Study details
Enrolling now
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Grifols Therapeutics LLC
NCT IDNCT05645107ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
386
Study length
about 3.5 years
Ages
18+
Locations
7 sites in CA, FL, MD +3
What this study is about
This trial is testing whether biweekly XEMBIFY® plus Standard Medical Treatment (SMT) will reduce the rate of major bacterial infections in people with B-cell CLL, MM, or NHL who have low antibody levels. Participants will receive either XEMBIFY® and SMT or a placebo and SMT for one year.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take Xembify
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Oncology